Back to Search
ORVILLE KOLTERMAN, M.D.
M.D.
Internal Medicine Physician
NPI: 1225061021Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
G31926(CA)
Endocrinology, Diabetes & Metabolism Physician
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
G31926(CA)
Research & Publications (20)
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
PMID 15700891·Am J Health Syst Pharm·2005
3-trial
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
PMID 12843147·J Clin Endocrinol Metab·2003
3-trial
Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
PMID 17259483·Diabetes Care·2007
2-rct
Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
PMID 17698615·Diabetes Care·2007
2-rct
Pharmacometrics and the transition to model-based development.
PMID 17632539·Clin Pharmacol Ther·2007
6-review
Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
PMID 17452962·Nat Clin Pract Endocrinol Metab·2007
8-other
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
PMID 17319471·Vasc Health Risk Manag·2006
6-review
A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
PMID 17003291·Diabetes Care·2006
4-observational
The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
PMID 16050943·Diabetes Obes Metab·2005
2-rct
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
PMID 15891954·Exp Clin Endocrinol Diabetes·2005
3-trial
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects.
PMID 15334389·Metabolism·2004
3-trial
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
PMID 15498087·Diabet Med·2004
3-trial
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
PMID 15090634·Obes Res·2004
3-trial
Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
PMID 14669170·Metabolism·2003
3-trial
Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.
PMID 14617226·Diabetes Obes Metab·2003
1-meta
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
PMID 14578242·Diabetes Care·2003
3-trial
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
PMID 12610038·Diabetes Care·2003
3-trial
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
PMID 12502651·Diabetes Care·2003
3-trial
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
PMID 12384827·Horm Metab Res·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 W ARBOR DR
SAN DIEGO, CA 92103 - Phone
- (858) 657-8000
Quick Facts
- NPI
- 1225061021
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile